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Abstract 
Wound healing is a complex process of biologicsl events involving re-
epithelialization and granulation that are mainly mediated by several endogenously 
released growth factors such as epidermal growth factor. This work was undertaken to 
study the effects of various doses of locally applied recombinant epidermal growth 
factor(rEGF) on wound healing in rats. In the test groups,rats was given daily with a 
solution containing 2,5,10,50,100ug of EGF spray and 40ug of EGF ointment. We 
presented evidence that a significant decreased healing time in wound was observed 
in all rhEGF groups when compared with the control,and reach to its maximal 
efficacy at 10ug/ml of rhEGF spray. The rate of wound closure was over 50 per cent 
at initial 3 days of treatment. Treatment with rhEGF significantly decreased the length 
of time to over 50 per cent healing by approximately 4- 5 days,and that to 70 per cent 
and 90 per cent healing by approximately 3- 4 days and 3 days,respectively. A 
stimulatory,dose-dependent effect of EGF on wound healing was observed with 
increased hEGF concentration. In toxicological test group, a dose of single 200ug or 
300ug within 24hours of subcutaneous and intramuscular rhEGF injection was given 
respectively,there were no significant adverse side effects. We recommended a 
proposal of clinical drug doses at 2ug,5ug and 10ug/ml of rhEGF spray,and 10ug and 
even higher 40ug rhEGF/g of ointment. The results indicated that prepared rhEGF by 
our group is safe,and is emerging in clinical effective use in assisting wound healing 
time. 
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Introduction 
Epidermal growth factor(EGF) is a broad variety of cellular regulator. EGF 
was firstly isolated by Cohen S(1) from a mouse submaxillary gland,and 
further purified mouse EGF. Its amino acid sequences was found to the 
relationship to urogastrone (2,3). EGF is a single polypeptide chain of 53 
amino acid residues and contain these intramolecular disulfide bonds that are 
required for biological activity. EGF is a heat stable protein and were 
destroyed during the isolation procedure by boiling . EGF could be still shown 
its biological activity at storage in room temperature for 2 years(4)(Chen LQ's 
data in chinese,2008). It has been reported that EGF promotes the proliferation 
and differentiation of cultured cells originated from ectoderm and mesodermal 
layers,such as epidermal cells, fibroblasts,myofibroblasts,keratocytes,corneal 
epithelial cells and angiogenesis, and a key importance on maintenance and 
impact organ development and a cascade of cellular events. In recent,It has 
been suggested that EGF could be beneficial in burn(5-7)、wound healing(8)、
diabetic foot ulcers(9-11) and digestive ulcer(12),and provide an attractive 
  
perspective. In addition,cosmetic containing EGF was found to be effective to 
improve the plasticity,to remove wrinkle,to show whitening and anti-
aging,and control of erythem amount and sebum amount on the human skin 
care. In local district, Zhu G in this field has successfully prepared a series of 
53 bottles of Shampo liquid (New Wash) into market,and responder rate with 
satisfied or perfect satisfied over 95 per cent. Actually,EGF is the secreted 
protein by epidermal cells in epidermis. Based on these data,the present work 
was undertaken to study the effects of various doses of locally applied EGF on 
rat wounds.  
Materials and Methods 
1.1. Wound model 
10 female Kunming(KM) strain rats (age 8 weeks, body weight 30-35g) were 
purchased from Hunan SJA Laboratory Animal Co., Ltd,Changsha,Hunan. 
The dorsal skin of the rats was sterized with iodophor and dorsal hair was 
shaved with clippers. An incision, 2cm length x 1.5cm width in diameter was 
made in the dorsal midline at the causal portion of the back using medical 
scissor and forceps. After full-thickness wound created on the back of the 
female back,wound sites were photographed daily. Wound area was measured 
with a ruler on day 0, 1,2,3,4,7, 8,10,13,15 after initial treatment. The surface 
area of the wound was calculated using the formula for calculation of the 
regular geometic figure that best approximated to the wound shape (area=a x 
b),where a and b represent the perpendicular length and width 
dimension,respectively. During the experiments,the animals received a normal 
diet and water ad libitum, and were housed individually in cages in animal 
quarter. All animal experiments were approved by the Animal Committee of 
Nanjing Origin Biosciences,Nanjing,China (OB1409). 
1.2. Preparation of recombinant epidermal growth factor(rhEGF) 
rhEGF used in the study was obtained as a donation from Prof. Zhi QW(13) in 
Institute of pharmacology and toxicology, academy of military medical 
sciences,Beijing. Using Bam HI and EcoR I  restriction enzymes, by genetic 
engineering(13-17) in 2002-2004 period of previous prepared methods, 
hEGFcDNA was cloned into pGEX-4T-1 plasmid system,pGEX-4T-1-hEGF 
prokaryotic expression vector bearing a tac promoter was constructed and 
production of human epidermal growth factor by Escherichia Coli  BL21 cells 
containing the pGEX-4T- 1-hEGF recombinant plasmid. The expression 
product was partially maintained in form of inclusion body. After the 
supernant of cell lysate subjected to Glutathione Sepharose 4B affinity 
chromatography,the purified rhEGF was obtained(figure 1), and its biological 
activity was detected by MTT methods. In the next step, the drug formulation 
was prepared by manufacturer Dr. Zhu G in this study at dose of 2, 5,10ug of 
rhEGF spray,and 10 and 40ug rhEGF/g of ointment. The rhEGF dose (10ug/g) 
was selected according to the therapeutic guideline of Brown's in USA(5) and 
Wong's in HongKong(11) and in Korea Kwon's(18) previous 
reports. Accordingly,as Gregory RA(2) described urogastrone earlierly, Dr. 
  
Zhu have also prepared rhEGF injection.  Laboratory data: Anti-HIV  0.077. 
No bacteria growth was shown as to rhEGF spray and liquid Shampo in 
bacteriological examination. 
All animals with a similar-sized wounds were randomly assigned to 7 
groups of 10 mice. Group 1 was treated with saline solution twice daily as the 
control. Group 2-4 was treated with 2、5、10ug of rhEGF spray twice 
daily,respectively. High doses of testing group 5 and 6 received 50 and 
100ug/ml of rhEGF spray, 5-10 times its clinical drug dosage,twice daily for 
15 days,and then once a day up to one month. Group 7,the drug rhEGF 
ointment (40ug rhEGF/g) was also administered topically to the animal every 
7-12 hour for 15 days and then once daily for next 15 days beginning on the 
day of the incision. Macroscopic assessment was carried out by an 
independent observer and recorded. Animal body weights and adverse reaction 
were recorded after the end of experiments. 
1.3. Data collection and statistical healing rate analysis 
Initial study data were gathered in table 2 and 3. Percentage wound closure 
was calculated using the formula: 
Wound healing rate = [ 1- Area of present wound / Area of initial wound ] x 
100% . Wound healing time and crude healing rate of wound were used to 
evaluate the efficacy of the treatment. The overall period of experimental 
procedure including genetic engineering in crude product of rhEGF was 
beginning from November, 2018 to June 25,2019,and pharmacological 
preparation of rhEGF spray and its animal wound test was from August 
29,2019 to January 13,2020. 
Results 
2.1.The biological activity of rhEGF 
For investigation,to examine the biological activity of 3T3 culture cells to a 
various dose of rhEGF using MTT methods,It has been uncovered that 
purified rhEGF spray was a potent stimulation of cell growth and proliferation 
when added to the cultured 3T3 cells at 6.4ng/ml of rhEGF concentration(table 
1A). In homogenous preparation of the same batch drugs,when storage as a 
frozen solution(-20℃), rhEGF could be shown its potent proliferative activity 
even at 3.13ng/ml of EGF concentration(table1B 3). As can be shown from 
table 1A and B, A dose- dependent cellular stimulation was observed with 
increased rhEGF concentration. The results indicated that purified rhEGF was 
proved validly in animal experimental wound model and clinical use. In this 
study,when we carried out the experiments by room temperature, rhEGF has 
still been found to maintain obviously its biological activity when stored at 4℃ 
for over 5 months. Therefore,if condition permit,rhEGF drug was preferably 
selected to stored at 4℃ refrigerator. 
2.2. rhEGF enhance wound healing 
Data of the effect of rhEGF on wound healing parameters were shown in table 
2 and 3 and figure 2. After daily application of various doses of rhEGF spray,a 
significant decreased healing time was observed when compared to the 
  
control.The rate of wound healing in all rhEGF groups was over 50 per cent at 
initial 3 days of treatment. Treatment with rhEGF significantly decreased the 
length of time to ver 50 per cent healing by approximately 5 days,and that to 
70 per cent and 90 per cent healing by approximately 3-4 days and at least 3 
days, respectively. In comparative analysis curve between these rhEGF 
groups(figure 3),wound healing at 2,5,10ug of rhEGF concentration was 
generally better effective than that in control,and reach to its maxmium 
efficacy at 10ug/ml of rhEGF spray( the healing rate: 57.5% at initial 3 
days,69.7% at days 5),while no difference was found as to the effects of 
rhEGF spray at 10-13 days. A higher dose of 100ug/ml of rhEGF bid for 5 
days appear to produce faster initial healing of the wound compared with 
control. During the duration of wound closure, A stimulatory effect of local 
rhEGF daily on granulation tissue formation was observed, accompanied with 
occasional microvillus hair. In contrast,two wounds were treated with only 
saline solution as control. There were 3 times of repeated bleeding in local 
surface of a wound,whereas surperficial seeping blood was found in the next 
day of incision in another mouse wound. This bloody wound was trying to 
iodophor and hemostasis with cotton ball pressure. The results suggested that 
rhEGF spray may play an antibiotic role and its possible hemostatic effect. 
 Surprising finding,the wound site was treated topically with 1% silver- 
sulfadiazine cream containing EGF(40ug/ml). It has been noted a significant 
higher efficacy of wound closure. Wound closure in wound was obviously 
accelerated at initial 3 days,and at 5 days the most parts of wound were 
scabbed, whereas scab abscission occurred at 7 days. Therefore,we concluded 
that the EGF has the ability to become an efficient therapeutic drug for 
surperficial or deep partial- thickness wound in skin. 
In throughout experiments of rhEGF spray at doses between 2- 100ug/ml,no 
significant adverse side effects has been observed in association with the use of EGF 
in this study regarding body weight and other (hair) growth-inhibiting effects even the 
incidence of infection in rats wounds. The complete wound healing including hair-
growth was observed at 25-28 days in all experimental rats. 
To further test whether rhEGF can be used as EGF saline injection, we carried out 
the additional experiments of subcutaneous and intramuscular injection of rhEGF 
solution in 2 rats,respectively. Initial dose of rhEGF was 20ug daily for 5 days,and 
escalated to 30ug daily for 5 days,then 50ug daily for 5 days,and the final volume 
100ug daily for 5 days.Total dosage of rhEGF was 1mg within 20 days. In 
toxicological test, a dosage of single 200ug or 300ug/24hours of subcutaneous and 
intramuscular rhEGF injection was given respectively in another 4 rats,which 20－
150 times its clinical drug at doses between 2-10ug. As we expected,there was no 
significant adverse side effects,except that a suspicious subcutaneous nodule was 
noted in one rat receiving continous application of rhEGF subcutaneously. Animal 
behavior of rats after a single injection at dose of 200ug or at 300ug/24hours of 
rhEGF solution was blunt in movement. The rats recovered their activity within 24 
hours, whereas an injection of rhEGF at doses of 400ug a day,40-200 times higher 
  
than its use in clinical drug doses, is lethal within 12-24 hours. The results indicated 
that prepared rhEGF is safe and available in clinical wound healing. 
Discussion 
In this study,we have demonstrated the potential efficacy of rhEGF as an 
adjunct to conventional wound repair,which have previously been confirmed 
by a number of in vitro and animal experiments(18,19),even though strain-
specific differences in wound healing rates may influence the true effect of 
EGF in the mouse models. The results are encouraging. 
From the dose effects curve,It has been shown that wound healing rates 
were generally better effects at 2-10ug of rhEGF ,and reach to a peak value of 
10ug/ml of rhEGF concentration. A comparision of dose-response rates also 
appears to the length of the best healing time at 10ug/ml of rhEGF. Certainly, 
daily application of 2 and 5ug of EGF were also available. The results were 
consistent with others Brown's (5) and in HongKong Wong's (11) observation. 
Brown and colleagues(5) carried out a large trial efficacy on 12 chronic 
wounds,they treated their patients initially with silvadene alone,which was 
ineffective in spite of its antibacterial action,for a peroid of 3 weeks to 6 
months. This was followed by treatment with topical silver sulfadiazine cream 
containing EGF(10ug/g),the addition of EGF producing a highly significant 
response. EGF significantly decreased the average length of time to 50 per 
cent healing by approximately one day and that to 75 per cent and 100 per cent 
healing by approximately 1.5 days(p < 0.02). 
The same group(20) in Finland also proved the stimulation of wound healing 
by EGF in dose-dependent effects. In the test group,wound were injected daily 
with a solution containing 0.2,1 or 5 ug of EGF in 0.1% albumin. EGF 
significant increases the accumulation of DNA and RNA,and accumulation of 
granulation tissue cells,collagen and glycosaminoglycans in experimental rat 
wounds. Dr. Zhu once experienced a 2.5x 2.5cm brush burn, the wound healed 
without scar at 5ug of rhEGF spray for 1 week. Indeed recent, my colleague 
Dr. Tang HL caught a knife wound (2 x2.5cm) by a table knife accident. The 
entire epidermis was striped off his forefinger. Blood flowed profusely from 
his right index finger. The wound healed without scar by the combination of 
5ug of rhEGF spray every other day and Yunan Baiyao spread within 20 days. 
Moreover, in Zhu's personal communication, a bone fracture attack by 
accident,caused severe swollen on the right leg of an animal chicken. The 
obvious disappearance of serious swollen was found at 3 days after local use 
of 5ug /ml of rhEGF spray,and 1 week late,the chicken could go on foot with a 
broken leg. The wound was gradually healing through the combination of 
local rhEGF spray and topical EGF-silvadence ointment(10ug/g) for 6 days. 
The results suggested that rhEGF may play its antibiotic role and its some 
benefits in a bone fracture 
Silver sulfadiazine(Ag-SD) is a useful antibacterial agent for wound treatment. 
Silver sulfadiazine indicated as an adjunct for the prevention and treatment of 
wound sepsis in patients with second- and third-degree burns. It is bactericidal 
  
for many gram-negative and gram-positive bacteria. Silver sulfadiazine acts 
only on the cell membrane and cell wall to produce its bactericidal effect. 
Silver ions bind to nuclear DNA,nucleophilic amino acids,as well as 
sulhydryl,amino, phosphate, and carboxyl groups in proteins,causing protein 
denaturation and enzyme inhibition. Silver binds to surface membranes and 
proteins,causing proton leaks in the membrane,leading to cell death. However, 
recent findings(21) indicate that Ag-SD delays the wound-healing 
process,while the addition of rhEGF could reverse the impairment. Therefore, 
A drug delivery system containing both EGF and Ag-SD,such as 1% silver 
sulfadiazine containing EGF(10ug/g) in this study,may be clinically relevant. 
In the study,we have shown EGF-Silvadene in the dual collaboration of both 
rhEGF on wound granulation tissue formation and antibacterial of silvadene. 
EGF-Silvadene ointment significantly decreased the length of healing time 
within initial 3 days,and that to over 90 per cent scabbed healing by 5 days. 
But at 1 week scab abscission occurred. Therefore,it is need to cover the 
wound with sterile gauze after topical rhEGF-silvadene cream,then fixed it 
with medical tape in order to its better drug efficacy. 
Many topics on the mechanism of hEGF action(5,12,22,23). Exogenous EGF 
could selectively bind to its receptor(EGFR) on cell membrane of keratocytes 
and fibroblasts in skin,and EGF induce initiation of DNA synthesis,activation 
of RNA and protein synthesis,and activation of the synthesis of extracellular 
macromolecules. It was reported that interaction between rhEGF and its 
receptor has to be maintained for 10-12 hours in order to achieve an effective 
cellular response in terms of better-organized granulation tissue,a greater DNA 
and protein content and a higher rate of cell replication(22). Using acetic acid-
induced gastric ulcer in rats, Liu and Xu(12) have reported that the numbers of 
EGF and its receptors obviously increased around ulcer margin at 2 days and 
reach its increased expression to a peak value at 4 days,and consequentially 
the peak was decline to a normal pattern. Gu et al (Gu YM's data in chinese) 
also observed that in health skin EGF and EGFR were weak positive,with its 
distribution of epithelial basal cells,and afterward the expression in wound 
became positive at 4 days,and at 10 days the EGF and EGFR were strong 
positive,with mainly distribution of epithelial basal cells around wound 
edge,dermal endothelial cells and fibroblasts. In addition to EGF-EGFR 
complexes, other increased PDGF and hydroxyproline contents were also 
locally acting factors. 
To evaluate the further stimulation of rhEGF in malignant ulcer, In 
Vitro transfection of NIH3T3 with a functional EGF receptor resulted in no 
significant alteration(0.4% colonies in soft agar) in growth properties(24,25). 
The same observation was shown that the 32D/EGFR cells which exhibited 
high levels of functional EGFR remained nontumorigenic during a 2-months 
period(26). However,EGF addition led to the formation of densely growth 
tranfected foci(~2x102 ffu/pM of DNA) in liquid culture and colonies(19.7%) 
in semisolid medium(25). Moreover,isolation of two distinct epithelial cell 
  
line K248C and K248P from a single feline mammary carcinoma with 
different tumorigenic potential in athymic mice,the K248C cells with 
amplification of the EGFR gene and elevated levels of RNA and protein were 
highly tumorigenic. The K248P were poorly tumorigenic(27). An oncogenic 
receptor EGFRvIII (28-33) which was first identified in primary human 
glioblastoma was revealed to be capable of abrogating IL-3-dependent 
pathway with tumorigenic activity(26). Thus,these results were consistent with 
the autocrine loop model postulated by Professor DF Stern and RA Weinberg 
(34) at Massachusetts Institute of Technology in which constitutive production 
of a mitogenic growth stimulatory signals by the EGFR in response to its 
normal ligand(EGF) or oncogenic mutations in gene encoding EGF receptor 
constitutively activating EGF receptor can lead to uncontrolled proliferation 
and cell transformation. EGF receptor overexpression appears to amplify EGF 
signal transduction. 
In Zhu's further communication, in March 28,2019, he consulted a patient with 
ulcerative laryngocarcinoma. The patient experienced the chief complaint of 
caugh、dyspnea and severe hoarse voice for over one month duration. A 
harden 5x7.5cm mass was palpable in his right neck region. After being 
applied with topical herbal paste by a doctor,the tumor was ulcerative and 
hemoptysis in sputum. There was a lot of exudate emitted from ulcerative 
wound,and the clothing neckline was wet almost every day. Meanwhile,the 
patient felt that exudate of the wound penetrated the lower part of his 
throat.The ulcer troubling caused him to undergo ulcer healing to improve his 
symptoms. It is not useful to spread Yunan Baiyao on the wound for more 
than two months,and other erythromycin ointment was also ineffecive. 
Moreover, the patient has used silver sulfadiazine ointment in another drug 
store for over one week,and the tumor tissue was bright red. When the patient 
was admitted to Zhu's clinic in June 8,2019,the protocol was consisted of the 
prescription of traditional medicine(TCM). After obtaining his consent,in 
August 29,2019,the patient was trying to topical EGF-Silvadene cream(rhEGF 
at initial 4 ug,then escalated to 7ug/g,twice daily) for 15 days,and then 
intermittent rhEGF cream use. At the third consultant,the hoarse voice of the 
patient was obviously improved,and the exudate of the wound was also 
significantly decreased. A close scrutiny uncovered granulation tissue 
hyperplasia and three neovascular nodules formation in ulcer wound. These 
data suggested that in addition to autocrine loop by tumor itself,exogenous 
rhEGF might accelerate the proliferative activity of malignant cells. Whether 
EGF can promote the growth of normal cells,accelerating the wound healing 
or to induce the incidence of tumor, it may depend on cell types of EGF 
action,internal and external environment and EGF concentration. Thus we are 
not yet able to draw a clear boundary between normal and abnormal cell 
growth(23,24,35). At present, because it is not necessary to target the normal 
receptor of health human cells, commercial antibodies for anti-oncogenic 
receptors within tumors(also anti-oncogenic receptor Abs)(Fu YX said in his 
  
Yang-xin Fu lab in UT Southwestern Medical Center,Dallas,Texas; Icotinib-
DrugBank)(36-47) have been developed available into market. Therefore,like 
G-CSF、GM-CSF、IGF-I、growth hormone and sex hormones(eg.estrogen 
and androgen),at least, use of G-CSF and GM-CSF are not without risk(Estey 
EH,1990). And more, in one rat,a suspicious subcutaneous nodule was noted 
in the continous application of rhEGF injection subcutanously. Long term 
application of EGF should therefore be paid attention to this action,especially 
in the most destructive trauma,such as a ulcerative cancer. 
In the present study,EGF administered by dorsal incision at a dose of 50 and 
100ug/ml,which is 5 to 10 times higher than its use in clinical doses,was 
evaluated for its toxic effects for 30 days in skin. Additional toxicological tests, 
an injection of single 200ug or 300ug/24hours of subcutaneous and 
intramuscular rhEGF solution was given respectively. No adverse side effects 
related to rhEGF was observed. Others, a stable body weight or behaviored 
signs in all groups indicated no obvious toxicity. In literature reports,another 
toxicological test was applied 6g (120ug/g) rhEGF gelatin to the skin wound 
for 36 days on the back of a rabbit, no adverse side effects regarding the local 
skin and organ toxicity was observed(data not shown). Moreover, in 
vivo overexpression of epidermal growth factor in transgenic mice could lead 
to growth retardation,but no tumor was observed in transgenic animals(48). In 
our study, we have realized in preparation of rhEGF medicine based on the 
experiments of an oncogenic pml/retinoic acid receptor alpha fusion (retinoid 
pharmacology) in APL and an aberrant androgen receptor with its 
methyltestosterone drug in the induction of breast tumors(29,30), and 
subsequentially the earliest discovery of normal or proto-oncogenic receptor 
kinase EGF receptor in cell proliferative signalling in wound healing,and in 
June, 1991 patent application for rhEGF powder and its specific Shampo 
liquid, and its newly Band-Aids. Here,from the principle of drug action,the 
EGF receptor to its EGF ligand seemingly compared to 'the key in the lock' . 
In conclusion, in spite of a number of confunding factors, our results and 
preliminary clinical trials support the intention that prepared hEGF by our 
group is more effective therapeutic agent in improving objective parameters of 
wound healing,and that it may assist in wound healing time. 
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Fig.1. Amino acid sequence of human epidermal growth factor 
 
 
 
 
 
 
  
 
 
 
Fig.2. A similar size wound before experiments(a,b,c) in control and test pair 
groups. After rhEGF treatment, an obvious wound closure in wound was shown at 
days 2(d, e) and days 5(f). From left to right in figure 1a control; figure 1b,5ug test 
rat; figure 1c,control(left) and 2ug(right)test rat. In figure 2d and 2e,rhEGF spray 
accordingly at 10ug, saline solution, or 5ug concentration. In figure 2f, a solution 
containing 10ug, 5ug, saline and 2ug/ml of rhEGF spray respectively. In figure 2g 
and 2h, wound area was measured with a ruler. 
 
 
 
 
 
 
 
  
 
Table 2.Experimental data of the wound healing time following various doses of rhEGF 
[Drug doses(ug/ml)/healing area(cm)/days] 
 
 
 
 
 
 
 
 
Area(cm2) 
mice 
No. 
Days 0 1 2 3 4 7 8 10 13 15 
control 2 2x1.5 1.5x1.5 1.5x1.4 1.5x1.3 1.5x1.2 1.4x1.1 1.4x1.0 1.1x0.8 0.7x0.4 0.5x0.3 
   25.0% 30.0% 35.0% 40.0% 48.7% 53.3% 70.7% 90.7% 95.0% 
  2.0x1.5 1.6x1.5 1.5x1.45 1.4x1.35 1.4x1.3 1.2x1.1 1.1x0.95 1.1x0.85   
   20.0% 27.3% 37.0% 39.3% 56.0% 65.2% 68.8%   
  1.8x1.8 1.7x1.4 1.5x1.2 1.5x1.15 1.5x1.1 1.15x1.0 1.1x0,9 0.9x0.8 0.65x0.5 0.5x0.4 
   26.5% 44.4% 46.8% 49.1% 64.5% 69.4% 77.8% 90.0% 93.8% 
2ug 1 2.5x1.5 1.5x1.4 1.3x1.3 1.3x1.1 1.3x1.0 1.2x1.0 1.0x0.8 0.7x0.5 0.5x0.3 0.3x0.2 
   44.0% 55.0% 61.9% 65.3% 68.0% 78.7% 90.7% 96.0% 98.4% 
5ug 2 2.5x2.0 1.8x1.5         
   46.0%         
  2.0x1.5 1.3x1.35 1.3x1.1 1.1x1.1 1.1x1.0 1.0x0.9 0.9x0.8 0.8x0.6 0.4x0.3 0.45x0.2 
   41.5% 52.3% 59.7% 63.3% 70.0% 76.0% 84.0% 96.0% 97.0% 
10ug 2 2.2x1.5 1.5x1.3 1.3x1.2 1.2x1.0 1.1x1.0 0.9x0.8 0.8x0.6 0.5x0.3 0.3x0.2 0.3x0.2 
   40.9% 52.7% 63.6% 66.7% 78.2% 85.5% 95.5% 98.2% 98.2% 
  2.0x1.5 1.3x1.45 1.1x1.05 1.1x1.0 0.9x0.9 1.0x0.9 0.7x0.65 0.7x0.6   
   37.2% 61.5% 63.3% 73.0% 70.0% 84.8% 86.0%   
  1.8x1.8 1.5x1.3 1.35x1.0 1.1x0.95 1.1x0.9 1.0x0.75 0.8x0.8 0.7x0.6 0.5x0.4 0.4x0.25 
   39.8% 58.3% 67.7% 69.4% 76.9% 80.2% 87.0% 93.8% 96.9% 
High Doses 
Test 
           
50ug 1 2.0x1.5 1.4x1.3 1.3x1.3 1.3x1.2 1.2x1.1 1.1x0.9 1.05x0.9 0.8x0.5 0.5x0.3 0.4x0.2 
   39.3% 43,7% 48.0% 56.0% 67.0% 75.5% 86.7% 95.0% 97.3% 
100ug 1 2.0x1.8 1.5x1.45 1.4x1.25 1.2x1.15 1.15x1.0 1.05x0.8 1.0x0.8 0.8x0.6   
   39.6% 51.4% 61.7% 68.1% 76.7% 77.8% 86.7%   
  1.5x1.5 1.1x1.0 1.0x0.9 0.95x0.9 0.9x0.9 0.8x0.7 0.7x0.6 0.6x0.55 0.4x0.3 0.3x0.2 
   51.1% 60.0% 62.0% 64.0% 75.1% 81.3% 85.3% 94.7% 96.0% 
40ug cream 1 2.0x1.5 1.3x1.1 1.1x1.0 0.8x0.7 0.3x0.3 0.7x0.6 0.8x0.5 0.7x0.4 0.4x0.3 0.3x0.2 
   52.3% 63.3% 81.3% 97.0% 86.0% 86.7% 90.7% 96.0% 98.0% 
  
Table 3.The Comparative data of wound healing rate at 2-10ug doses of rhEGF spray(Days(healing 
per cent) 
Group Exp. 
No. 
Days 
1  
   2     3 4 5 6 7 8 9 10 11 13 15 
control 3 23.8 33.9 39.6 42.8 52.1 
n=2 
53.2 
n=2 
56.4 62.6 67.2 72.4 84.9 
n=1 
90.4 94.4 
2ug 1 
 
44.0 55.0 61.9 65.3   68.0 78.8  90.7  96.0 98.4 
5ug 1 43.8 
n=2 
52.3 59.7 63.3 63.3 
 
66.7 70.0 76.0 77.8 84.0 92.0 96.0 97.0 
10ug 3 39.3 57.5 64.9 69.7 73.4 
n=2 
74.1 
n=2 
75.0 83.5 84.5 89.5 92.3 
n=1 
96.0 97.6 
50ug 1 39.3 43.7 48.0 56.0   67.0 77.5  86.7  95.0 97.3 
100ug 2 45.4 55.7 61.9 66.1 69.4 
 
72.3 75.9 79.6 84.4 86.0 91.1 94.7 96.7 
 
 
 
  
 
